ClinicalTrials.gg
Not yet recruitingNCT07241273SELECT-FRUpdated Jul 21, 2026

SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer

An interventional study of Lymphatic mapping with SPECT-CT and Bilateral neck radiotherapy in Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Cancers and Oropharyngeal Carcinoma, sponsored by UNICANCER. Not yet recruiting at 12 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by UNICANCER · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Squamous Cell Carcinoma of Head and Neck by UNICANCER — 4 open to participants now, 4 under way, 1 of them phase 3. Squamous Cell Carcinoma of Head and Neck · UNICANCER.

Planned enrollment
6th of 11
128 · median 128
Started
2026
with 1 other
No phase
4 of 12
2 open now
Registered
12th of 12
by date

Among the 12 studies in Squamous Cell Carcinoma of Head and Neck by UNICANCER, this one is the 6th largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2026, is one of 4 with no phase, and was the 12th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

4 of the 12 studies in Squamous Cell Carcinoma of Head and Neck by UNICANCER are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Squamous Cell Carcinoma of Head and Neck by UNICANCER, or all of them as a file.
02

Study summary

Oropharyngeal cancer (OPC) is the most common type of head and neck cancer. The current standard treatment for this cancer is radiotherapy (RT) of the tumour and lymph nodes of both sides of the neck, combined with concurrent chemotherapy for advanced stages. Even though a small proportion of patients with this cancer have involvement of the lymph nodes of the neck on the opposite side of the tumour (contralateral involvement) or involvement of the lymph nodes on both sides of the neck (bilateral involvement), bilateral radiotherapy is performed due to the risk of contralateral microscopic involvement, which is invisible on imaging and clinical examination. Bilateral radiotherapy causes more adverse events, leading to a decrease in quality of life.

Lymphatic mapping using Single Photon Emission Computed Tomography-Computed Tomography (SPECT-CT) imaging is a technique that visualises the lymphatic drainage of the tumour and thus determines whether radiotherapy should be delivered unilaterally or bilaterally to the lymph nodes. This technique would therefore reduce adverse events and improve quality of life, while maintaining the efficacy of radiotherapy.

The goal of the clinical trial SELECT-FR is to investigate if the efficacy of a lymphatic drainage mapping with a SPECT-CT-guided approach is acceptable in terms of two-year Disease Free Survival (DFS) rate in patients with lateralized OPC.

Read the detailed description

SELECT-FR is a national, randomized, phase II, non-comparative trial.

Patients aged 18 or over, with lateralized oropharyngeal squamous cell carcinoma (tonsil, soft palate, pharyngeal wall or tongue base) not involving or crossing midline, Human Papilloma Virus (HPV) positive or negative, T1-T3 with no contralateral nodes or nodes > 6 cm on Computed Tomography (CT), Magnetic Resonance Imaging (MRI) or Positron Emission Tomography-Computed Tomography (PET-CT).

Eligible subjects will be randomized at a 1:1 ratio into the experimental and control arms.

  • Experimental arm: Patients will receive definitive RT to the primary tumour and ipsilateral neck nodes, while contralateral neck RT treatment will be guided by lymphatic mapping with SPECT-CT.
  • Control arm: Patients will receive definitive RT to the primary tumour and bilateral neck nodes (Note: candidates for standard unilateral neck RT are not eligible).

Randomization will be stratified by the following factors:

  • Anatomical location of primary tumour: lateral vs. intermediate vs. medial.
  • HPV status (p16 immunohistochemistry) and smoking status: p16 positive ≤ 10 pack year vs. p16 positive > 10 pack year vs. p16 negative any.
  • Extent of disease: limited vs. other:

    • p16 positive: limited [T1-T2, N0-N1 (single node \< 3cm without radiologic extranodal extension)] vs. other.
    • p16 negative: limited [T1-T2, N0-N1 (without radiologic extranodal extension)] vs. other.
  • Use of concurrent systemic therapy: yes vs. no.

In both arms, time from randomization to initiation of RT will be no longer than 6 weeks. Patients will receive RT with or without standard concurrent chemotherapy in either standard fractionation (7 weeks) or altered fractionation (6 weeks).

In both arms, all patients will be followed by local investigator as follow:

  • Treatment period: every week.
  • Follow-up period: every 3 months until 24 months after treatment and then every 6 months until 36 months after treatment.
03

Conditions studied

  • Oropharyngeal Squamous Cell Carcinoma
  • Oropharyngeal Cancers
  • Oropharyngeal Carcinoma
  • Head and Neck
  • Head and Neck Cancer
  • Head and Neck Cancers
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients must have signed a written form prior to any trial specific procedures.
  2. Patients with confirmed T1-T3 M0 lateralized OPC (tonsil, soft palate, pharyngeal wall or base of tongue) not involving or crossing midline. Nodal disease may include no node or single or multiple ipsilateral lymph nodes (largest should be equal or less than 6 cm in maximum diameter) without contralateral nodes involved. For HPV-positive patients, this includes N0-N1. For HPV-negative patients, this includes N0-N2b. Patients with radiologic extranodal extension without clinical signs of extranodal extension (skin invasion, deep nodal fixation, and/or clinical signs of cranial nerve or brachial plexus invasion) will be eligible for participation.
  3. HPV-positive or -negative (by p16 immunohistochemistry). Tumours will be classified as p16 at local sites based on greater than 70% strong diffuse nuclear or nuclear and cytoplasmic staining.
  4. Planned definitive bilateral neck radiotherapy with or without concurrent chemotherapy.
  5. Patients ≥ 18 years old.
  6. Performance Status 0-1.
  7. The following radiological investigations must have been done within 8 weeks before randomization:

    • CT or MRI of the neck (with head imaging as indicated);
    • PET-CT scan;
    • Chest CT scan.
  8. Patients who receive a concomitant chemoradiotherapy (cCRT) should have adequate organ and bone marrow function including the following:

    • Hematological function ( ≥ 1.5 x10⁹/L, ≥ 100 x10⁹/L, ≥ 9 g/dL) measured before cCRT.
    • Renal function ( ≥ 50 mL/min per Cockcroft and Gault formula) measured before cCRT.
    • Hepatic function (total \< 1.5 , (AST) and Alanine aminotransferase (ALT) \< 2.5 ULN, Alkaline phosphatase \< 2.5 ULN) measured before cCRT.
  9. Women/men of must have agreed to use a highly effective method up to 90 days after completing radiotherapy.

    Women of childbearing potential must have a negative pregnancy test before the beginning of the trial.

  10. Treating surgeon must confirm that the patient is a candidate to undergo injection procedure for lymphatic mapping in either the nuclear medicine, ambulatory clinic, or operating room setting.
  11. Patient is willing and able to comply with the protocol for the duration of the trial including undergoing treatment and scheduled visits, and examinations including follow-up.
  12. Patients affiliated to (or beneficiary from) the French social security system.
  13. Patients with a prior or concurrent whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the regimen are eligible for this trial.

Exclusion criteria

Exclusion Criteria:

  1. Patients with T1-T2 cancers isolated to the tonsil fossa (i.e., without any soft palate, tongue base, posterior pharyngeal wall or posterior tonsil pillar involvement) with no involved lymph nodes or with a single ipsilateral node \< 3 cm without extranodal extension.
  2. Patients with tonsil or tongue base primary squamous cell carcinoma who have previously undergone diagnostic palatine or lingual tonsillectomy with either complete excision or with no clinically apparent residual disease are excluded. However, patients who have had previous deep or partial excisions with clinically evaluable disease are still eligible.
  3. Previous head and neck cancer or multiple synchronous primary head and neck cancers.
  4. Previous induction or chemotherapy.
  5. Previous radiation therapy to the head and neck or comprehensive neck dissection of at least 3 levels on either side (due to potential for disrupted lymphatic channels and drainage pathways). Patients who have had excisional biopsies of involved lymph nodes are, however, still eligible.
  6. Previous radiotracer allergy. in patients with history of to human albumin-containing products.
  7. Patients with severe, active co-morbidity including any of the following:

    • or other pulmonary illness requiring hospitalization within 30 days of registration.
    • Unstable angina and/or congestive heart failure requiring hospitalization within the 30 days of registration.
    • Acute myocardial infarction within 30 days of study registration.
    • Diseases precluding RT (e.g., scleroderma).
  8. Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule, as assessed by the investigator.
  9. Pregnant or breastfeeding women.
  10. Patient enrolled in another therapeutic trial within 30 days of registration.
  11. Persons deprived of their liberty or under protective custody or guardianship.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
128 participants (estimated)

Study arms

  • Experimental
    Ipsilateral neck radiotherapy & SPECT-CT guided contralateral neck radiotherapy

    Radiotherapy of ipsilateral neck nodes \& Radiotherapy of the contralateral neck nodes guided by SPECT-CT

    Other: Lymphatic mapping with SPECT-CT · Radiation: Ipsilateral neck radiotherapy & SPECT-CT guided contralateral neck radiotherapy

  • Active comparator
    Bilateral neck radiotherapy

    Radiotherapy of nodes on both sides of the neck

    Radiation: Bilateral neck radiotherapy

Interventions

  • OtherLymphatic mapping with SPECT-CT

    Lymphatic mapping with SPECT-CT

  • RadiationBilateral neck radiotherapy

    Patients will receive definitive radiotherapy to the primary tumour and bilateral neck nodes.

  • RadiationIpsilateral neck radiotherapy & SPECT-CT guided contralateral neck radiotherapy

    Patients will receive definitive radiotherapy to the primary tumour and ipsilateral neck nodes while radiotherapy to the contralateral neck nodes will be guided by lymphatic mapping with SPECT-CT.

06

What researchers measure

Primary outcomes

  1. Two-years Disease Free Survival (DFS) rate

    The primary endpoint is 2 year-Disease-Free Survival rate (2y-DFS) defined as patients free of disease at two years. Patients without any event before 2 years will be considered as success, patients lost to follow-up before 2 years will be considered as failure.

    Time frame: At 2 years after treatment

Secondary outcomes

  1. Disease free survival

    Disease-free survival (DFS) is defined as time from randomization to the date of first record of any of the following events including local, regional, or distant recurrence or death from any cause. DFS will be censored on the date of last visit with disease assessment.

    Time frame: From randomization to any of the following events: local, regional, or distant recurrence or death from any cause, up to 3 years after treatment.

  2. Overall survival (OS)

    Overall survival (OS) is defined as the time from the date of randomization to the date of death from any cause. The follow-up of subjects still alive will be censored at the date of last visit/contact.

    Time frame: From randomization to the date of death from any cause, up to 3 years after treatment.

  3. Isolated Contralateral Neck Failure (iCNF)

    Isolated Contralateral Neck Failure (iCNF) is defined as the time from the date of randomization to the date of iCNF. Local ipsilateral neck failure, or distant failure diagnosed concurrently with iCNF or before are not considered events of interest but as competing risks events in the analysis of this endpoint. Subjects without any of the listed events (i.e. events of interest or competing risks events) are censored at the date of the most recent follow-up examination.

    Time frame: From randomization to the date of iCNF, up to 3 years after treatment.

  4. Local-regional failure (LRF)

    Local-regional failure (LRF) is defined as the time from the date of randomization to the date of any local or regional failure. Distant recurrence/progression diagnosed before local or regional failure are not considered events of interest, but as competing risks events in the analysis of this endpoint. Subjects without any of the listed events (i.e. events of interest or competing risks events) are censored at the date of the most recent follow-up examination.

    Time frame: From randomization to the date of any local or regional failure, up to 3 years after treatment.

  5. Distant metastases (DM)

    Distant metastases (DM) are defined as clear evidence of distant metastases in the lung, bone, brain, liver or other distant sites. Biopsy is recommended where possible according to local practices. Distant sites can be evaluated by CT scans or PET-CT. Distant metastasis free survival is defined as the time from the date of randomization to the date of distant metastases. All other events are not considered events of interest, but as competing risks events in the analysis of this endpoint.

    Time frame: From randomization until clear evidence of distant metastasis, up to 3 years after treatment.

  6. Incidence and Severity of Treatment-Related Adverse Events

    Toxicities will be measured using the National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5.0). The NCI-CTCAE is a descriptive terminology which can be used for Adverse Event (AE) reporting and it is widely accepted in the community of oncology research as the leading rating scale for adverse events. A grading (severity) scale is provided for each AE term. This scale is divided into 5 grades (1 = "mild", 2 = "moderate", 3 = "severe", 4 = "life-threatening", and 5 = "death"). Toxicities will be measured by the investigator weekly during Radiotherapy (RT), at 1 month and 3 months after completion of RT to assess acute toxicities and then at each follow up visit following completion of RT to assess late toxicities until 36 months post RT.

    Time frame: Throughout study completion, up to 3 years after treatment.

  7. Incidence and Severity of Treatment-Related Adverse Events reported by patients (using items of PRO-CTCAE)

    Patient reported toxicities will be evaluated using selected items of the validated Patient-Reported Outcome-Common Terminology Criteria for Adverse Events (PRO-CTCAE). It is recognized that clinician-reported adverse events (AEs) may substantially under-report the incidence and severity of symptoms occurring as a consequence of treatment. In response to this awareness, the NCI has developed a set of patient-reported items (called PRO-CTCAE) that complement the CTCAE and capture the patient's perspective on the subjective aspects of adverse events. PRO-CTCAE H\&N information will complement the clinician CTCAE reporting. A collection of 15 specific PRO-CTCAE Head \& Neck (H\&N) items is proposed. Patient reported toxicities will be evaluated at baseline, end of treatment, 12, and 24 months after the end of treatment.

    Time frame: Throughout study completion, up to 2 years after treatment.

  8. Gastrostomy tube usage

    Gastrostomy tube usage will be assessed for the presence of a gastrostomy tube as well as usage of the gastrostomy tube at each visit until tube removal.

    Time frame: Throughout study completion, up to 3 years after treatment.

07

Study locations

12 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Sep 2030, 48 months later.

Of 116 non-industry interventional studies with no phase under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 90. This study's planned 48 months is below that.

Counting every sponsor, half of 127 studies reached it within 59 months; a quarter within 34 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2025
First posted
Nov 21, 2025
StartEst.
Sep 2026
Primary completionEst.
Sep 2030
CompletionEst.
Sep 2031
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07241273
Lead sponsor
UNICANCER
Collaborators
National Cancer Institute, France
Responsible party
Sponsor
First posted
Nov 21, 2025
Start date
Sep 2026 (estimated)
Primary completion
Sep 2030 (estimated)
Completion
Sep 2031 (estimated)
Last update
Jul 21, 2026

Study contacts

Sébastien THUREAU, MD
study chair · Centre Henri Becquerel

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion